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SOE uses 2 primer pairs consisting of 
one wildtype and one mutagenic 
primer. This diagram shows a and d as 
flanking primers and c and b as 
mutagenic primers.
Construction of a mutant 
transcript via SOE-PCR
Fig 1. Results of SOE-PCR. 
Confirmatory Gel 
Electrophoresis after 
amplification of full mutant 
transcript. Excpected band 
size: 600 bp.
Map of pTarget vector. pTarget works 
with TA cloning making it compatible 
with any gene sequence with 3'-A 
overhangs that anneal with the 3'-T 
overhangs in the vector.




Fig 2. Blue-White screening 
results after  ligation and 
transformation. The colonies with 
positive insert (white colonies) 
were subject to alkaline lysis 
extraction.
Resitriction Enzyme digestion 
via EcoRI
Fig 3. RE Digest results showing 
successful cloning. Three bands can 
be found in the lanes of clones with 
positive inserts. The highest band at 
5kbp is the linearized vector, and the 
lower two bands (500bp and 200bp) 
are for the insert containing an 
internal RE site for EcoR1. The multiple 
cloning sites are also accounted in the 
total insert length, 700bp, of the 
resulting bands. (KRAS is only 600 bp)
Sequencing and alignment
Fig 4. Protein Sequence 
alignment through Blastx. 
Aimed amino acid sequence 
was obtained (A), and 
identities matched (B) despite 
an unintended mutation found 
in the nucleotide sequence, 
and only the aimed amino acid 
mutation was obtained (C). 
Background Methodology + Results
                                                                                                    The overexpression vector for the gene encoding    
                                                                                                    for KRAS contain the noncanonical mutation R164L 
was successfully cloned. The resulting clones shall now be utilized through various functional characterization 
assays. Various Molecular Biological concepts such as cancer mutations and MolBio techniques were learned 
throughout this study.
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